Cardiket, 20 mg 50 pcs

Cardiket is a vasodilator.

Pharmacodynamics

Isosorbide dinitrate causes relaxation of the vascular smooth muscle wall, thus inducing vasodilation. Isosorbide dinitrate acts as a peripheral vasodilator, affecting both arteries and veins. These effects contribute to the deposition of venous blood and decrease venous return to the heart, reducing end-diagnosis and left ventricular volume (reduce preload).

Long-acting Cardiket is characterized by a combination of rapid onset of effect and duration of action.

The benefits of the drug are determined by the fact that the active substance contained in the Cardiket® ^{rolonged-action tablet is rapidly released into the bloodstream. As a result, the drug provides a rapid onset of effect in the treatment of angina pectoris and retains its protective effect for a long time.}

Pharmacokinetics

Isosorbide dinitrate is rapidly absorbed when taken orally. Bioavailability when taken orally is 22% (effect of “first passage” through the liver). Onset of action is in 15-30 minutes, C_max of the substance in blood plasma is reached in 15 minutes to 1-2 hours. As a result of passage through the liver, isosorbide dinitrate is metabolized to form isosorbide-2-monononitrate and isosorbide-5-monononitrate, which have T_1/21.5-2 and 4-6 h respectively. Both metabolites are pharmacologically active. Excreted by the kidneys (almost completely as metabolites). Binding to plasma proteins is 30%.

Indications

attacks of all forms of angina
prevention of angina pectoris
acute myocardial infarction
chronic heart failure.

Pharmacological effect

Cardiket is a vasodilator.

Pharmacodynamics

Isosorbide dinitrate causes relaxation of the smooth muscle wall of blood vessels, thereby inducing vasodilation. Isosorbide dinitrate acts as a peripheral vasodilator, affecting both arteries and veins. These effects promote the deposition of venous blood and reduce venous return to the heart, reducing final dBP and left ventricular volume (reduce preload).

Long-acting cardiket is characterized by a combination of rapid onset of effect and duration of action.

The advantages of the drug are determined by the fact that the active substance contained in the Kardiketa® prolonged-release tablet quickly enters the bloodstream. As a result, the drug provides a rapid onset of effect in the treatment of angina pectoris and retains its protective effect for a long time.

Pharmacokinetics

When taken orally, isosorbide dinitrate is rapidly absorbed. Bioavailability when taken orally – 22% (first pass effect through the liver). The onset of action is after 15-30 minutes, the Cmax of the substance in the blood plasma is reached after 15 minutes – 1-2 hours. As a result of passage through the liver, isosorbide dinitrate is metabolized to form isosorbide-2-mononitrate and isosorbide-5-mononitrate, which have T1/21.5-2 and 4-6 hours, respectively. Both metabolites are pharmacologically active. Excreted by the kidneys (almost entirely in the form of metabolites). Binding to blood plasma proteins is 30%.

Special instructions

Cardiket retard should not be prescribed for the purpose of relieving an attack of angina.

Severe headaches that occur at the beginning of therapy, in most cases, are significantly reduced or completely disappear with continued use of the drug.

You should avoid drinking alcohol during treatment with Cardiket.

Impact on the ability to drive vehicles and operate machinery

The question of the possibility of engaging in potentially hazardous activities should be decided only after assessing the patient’s individual response to the drug.

Active ingredient

Isosorbide dinitrate

Composition

Active ingredient:

isosorbide dinitrate 20 mg;

Excipients:

lactose monohydrate;

talc;

magnesium stearate;

polyvinyl acetate;

potato starch

Contraindications

acute phase of myocardial infarction
marked decrease in blood pressure
hypersensitivity to the drug Cardiket

Side Effects

From the cardiovascular system: at the beginning of treatment – severe headache (caused by dilatation of the venous bed of the cerebral vessels); possible – tachycardia, orthostatic hypotension.

From the side of the central nervous system: drowsiness.

From the gastrointestinal tract: in some cases – nausea, vomiting.

Dermatological reactions: in some cases – erythematous rashes.

Interaction

With the simultaneous use of Cardiket retard with antihypertensive drugs, cyclic antidepressants, MAO inhibitors, its hypotensive effect may be enhanced.

When used simultaneously, Kardiket retard potentiates the effect of dihydroergotamine and ethanol.

Overdose

Symptoms: headache, palpitations, dizziness, arterial hypotension, nausea, vomiting.

Treatment: symptomatic.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

5 years

Manufacturer

Eisika Pharmaceuticals GmbH, Germany